Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Sunday the presentation of positive overall survival (OS) results from the randomised, double-blind, multicentre, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organised by the International Association for the Study of Lung Cancer (IASLC).
The study evaluated the company's first-in-class next-generation immuno-oncology therapy, ivonescimab, versus pembrolizumab as first-line treatment for patients with PD-L1-positive (PD-L1 TPS greater than 1%) locally advanced or metastatic non-small cell lung cancer (NSCLC).
As of the data cutoff on 20 August 2026, the median follow-up was 36 months, and a total of 234 overall survival (OS) events had occurred. For this OS analysis, a prespecified O'Brien-Fleming spending function was used, with a one-sided alpha of 0.0141.
According to Akeso, results showed that, compared with pembrolizumab, first-line treatment with ivonescimab significantly prolonged OS in patients with PD-L1-positive advanced NSCLC. This finding met the prespecified statistical significance threshold and demonstrated clear clinical benefit. The overall survival benefit was generally consistent across prespecified subgroups, with particularly pronounced benefit observed in the PD-L1-high population.
In May 2024, a prespecified interim analysis of progression-free survival (PFS) confirmed that HARMONi-2 met its primary PFS endpoint with statistically significant and clinically meaningful results. Median PFS was 11.14 months with ivonescimab versus 5.82 months with pembrolizumab.
HARMONi-2 is the first randomised, double-blind, controlled Phase III clinical study to demonstrate statistically significant positive OS and PFS results versus pembrolizumab, the company said.
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
Oracle partners AstraZeneca for AI-enabled healthcare innovation
GSK reports 61% response rate for investigational lung cancer drug
Omeros receives negative EU opinion on narsoplimab after re-examination
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Sophos IRB and ALCMI partner to support lung cancer research
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK